Pharmacoeconomic analysis of venlafaxine in the treatment of major depressive disorder

PharmacoEconomics

Volumn 12, Issue 2 II, 1997, Pages 286-296

  Einarson, Thomas R ^a,b,c   Addis, Antonio ^a   Iskedjian, Michael ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

^c MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; DESIPRAMINE; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; NORTRIPTYLINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DEPRESSION; HOSPITAL CARE; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; OUTPATIENT CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICS;

EID: 0030882808     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-199712020-00019     Document Type: Article

References (25)

1. Greenberg PE, Stiglin LE, Finkelstein SN, et al. The economic burden of depression in 1990. 3 Clin Psychiatry 1993; 54: 405-18
2. Jonsson B, Bebbington PE. What price depression? The cost of depression and the cost-effectiveness of pharmacological treatment. Br J Psychiatry 1994; 164: 665-73
3. Morton WA, Sonne SC, Verga MA. Venlafaxine: a structurally unique and novel antidepressant. Ann Pharmacother 1995; 29: 387-95
4. Asberg M, Eriksson B, Martensson B. Therapeutic effects of serotonin uptake inhibitors in depression. J Clin Psychiatry 1986; 47: 23-35
5. Cole JO, Bodkin JA. Antidepressant drug side effects. J Clin Psychiatry 1990; 51: 21-6
6. Ellingrod VL, Perry PJ. Venlafaxine: a heterocyclic antidepressant. Am J Hosp Pharm 1994; 51: 3033-46
7. McCombs JS, Nichol MB, Stimme! CL, et al. The cost of antidepressant drug therapy failure: a study of antidepressant use patterns in a Medicaid population. J Clin Psychiatry 1990; 51 : 60-9
8. Guidelines for economic evaluation of pharmaceuticals: Canada. 1st ed. Ottawa: Canadian Coordinating Office for Health Technology Assessment, Nov. 1994
9. Ontario guidelines for economic analysis of pharmaceutical products. Toronto: Ministry of Health Ontario, 1994
10. Revicki DA, Brown RE, Palmer W, et al. Modelling the cost effectiveness of antidepressant treatment in primary care. Pharmacoeconomics 1995; 8: 524-40
11. Wilde MI, Whittington R. Paroxetine: a pharmacoeconomic evaluation of its use in depression. Pharmacoeconomics 1995; 8:62-81
12. O'Brien BJ, Novosel S, Torrance G, et al. Assessing the economic value of a new antidepressant: a willingness to pay approach. Pharmacoeconomics 1995; 8: 34-45
13. Einarson TR, Arikian SR, Sweeney S, et al. A model to evaluate the cost effectiveness of oral therapies in the management of patients with major depressive disorders. Clin Ther 1995; 17: 136-53
14. Milholland AV, Wheeler SG, Heieck JJ. Medical assessment by a Delphi group opinion technic. N EngI J Med 1973; 288: 1272-5
15. Moscovice I, Armstrong P, Shortell S, et al. Health services research for decision-makers: the use of the Delphi technique to determine health priorities. J Health Polit Policy Law 1997; 3:388-410
16. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56-62
17. Montgomery SA, Asberg M. A new depression scale designed to be more sensitive to change. Br J Psychiatry 1979; 143: 382-9
18. Drug Benefit Formulary/Comparative Drug Index. Toronto: Ontario Ministry of Health, Dec 1,1994 (Revised Jun 2,1995)
19. PPS. Monoton NB: Total Pricing Systems Inc, Jul 1996
20. Schedule of benefits: physician services under the Health Insurance Act. Toronto: Ontario Ministry of Health, 1992, Oct 1
21. Hospital Statistics 1991/92. Toronto: Ontario Ministry of Health, 1994
22. LePen C, Levy E, Ravily V, et al. The cost of treatment dropout in depression: a cost-benefit analysis of fluoxetine vs tricyclics. J Affect Disord 1994; 31: 1-18
23. Data on file, Wyelh-Ayerst Canada. Study no. 652. North York, Ontario, Canada
24. Nelson JC, Mazure CM, Bowers Jr MB, et al. A preliminary, open study of the combination of fluoxetine and desipramine for rapid treatment of major depression. Arch Gen Psychiatry 1991:48:303-7
25. Newman RH, Janicak PC. Augmentation strategies in treatment-resistant affective disorder. Curr Opin Psychiatry 1991; 4: 65-9